Phase II trial of dacomitinib, a pan–human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification

BACKGROUND: We conducted a multicenter, 2-stage, open-label, phase II trial to assess the efficacy and safety of dacomitinib in adult patients with recurrent glioblastoma (GB) and epidermal growth factor receptor gene (EGFR) amplification with or without variant III (EGFRvIII) deletion. METHODS: Pat...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Neuro Oncol
Autori principali: Sepúlveda-Sánchez, Juan Manuel, Vaz, María Ángeles, Balañá, Carmen, Gil-Gil, Miguel, Reynés, Gaspar, Gallego, Óscar, Martínez-García, María, Vicente, Elena, Quindós, María, Luque, Raquel, Ramos, Ana, Ruano, Yolanda, Pérez-Segura, Pedro, Benavides, Manuel, Sánchez-Gómez, Pilar, Hernández-Laín, Aurelio
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2017
Soggetti:
Clinical Investigations
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5737732/
https://ncbi.nlm.nih.gov/pubmed/28575464
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox105
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi